Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Dermira (DERM) on November 19 and set a price target of $20. The company’s shares closed on Wednesday at $10.89, close to its 52-week low of $6.98.
According to TipRanks.com, Fernandez is a 4-star analyst with an average return of 10.6% and a 53.8% success rate. Fernandez covers the Healthcare sector, focusing on stocks such as Revance Therapeutics, Sanofi-Aventis Sa, and GlaxoSmithKline.
Currently, the analyst consensus on Dermira is a Moderate Buy with an average price target of $18, implying a 65.3% upside from current levels. In a report issued on November 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $20 price target.
The company has a one-year high of $31.42 and a one-year low of $6.98. Currently, Dermira has an average volume of 525.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.